In this study, the frequency of promoter methylation of eight candidate genes (MGMT, CALCA, VGF, HOXA9, NANOG, CDKN2B, CDO1 and ADAMTS1) was evaluated to assess a set of potential biomarkers that would accurately discriminate clinical outcome of patients with TGCT. This evidence concerns the gene VGF and testicular germ cell tumor.